Neuromonics third clinical trial (two active variants, no control)

Record details

Authors: Davis PB, et al.
Journal / source: Ear & Hearing (2007)
Design: Randomized comparison of TWO VARIANTS of the same Neuromonics treatment — no untreated or sham arm
Sample: 35
Primary endpoint: Tinnitus Reaction Questionnaire (distress) at 6 months
Randomized: Yes · Sham/placebo-controlled: No · Independent of the manufacturer: No

What this research found

91% had ≥40% TRQ improvement (mean 65%) — but with no independent control arm, this cannot be attributed to the treatment rather than placebo/natural course.

Frequently quoted by marketing as '91% success'; the design cannot support that framing. Registration and funding details unable to verify from the record read.

Limitations and conflicts of interest

No control group; company-run.

Funding / conflicts: Company-affiliated (manufacturer-linked research program).

Primary sources

Used as evidence for

Neuromonics (and other discontinued cleared devices)

This is an original summary from the Tinnitus Evidence verified database, checked against the primary source — not a reproduction of the publisher's abstract.